Ketamine was first synthesized in 1962 and was approved by the FDA as an anesthetic agent in 1970. Because of its relatively safe side effect profile and its efficacy as an analgesic agent, the World Health Organization lists ketamine as a “Core” agent, meaning it is on the list of essential medications needed at all basic hospital settings. In the 1990s, ketamine infusion started to be studied for the treatment of depression. Studies have shown that both ketamine infusion and intranasal esketamine are extremely effective for treatment-resistant depression.
For many patients who have tried antidepressants without success, intranasal esketamine works quicker, more effectively, and with minimal side effects. Feelings of dissociation and elevated BP can occur 1-2 hours after it administration.
Intranasal esketamine treats depression within hours whereas antidepressant medications take at least 2 to 4 weeks to start working.
Intranasal esketamine, brand name Spravato, is now FDA approved and often covered by insurance. Please visit us at our website devoted to esketamine treatment to learn more about it and see if you may be a candidate, by clicking below.
SUBMIT YOUR INFO AND WE’LL GET BACK TO YOU.
FOR EMERGENCIES, PLEASE VISIT OUR RESOURCES SECTION.